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Abstract
The delta-opioid receptor (DOR) belongs to the superfamily of G-protein-coupled receptors
(GPCRs) with seven transmembrane domains, and its membrane trafficking is regulated by
intracellular sorting processes involving its C-tail motifs, intracellular sorting proteins, and several
intracellular signaling pathways. In the quiescent state, DOR is generally located in the intracellular
compartments in central neurons. However, chronic stimulation, such as chronic pain and
sustained opioid exposure, may induce membrane trafficking of DOR and its translocation to
surface membrane. The emerged functional DOR on cell membrane is actively involved in pain
modulation and opioid analgesia. This article reviews current understanding of the mechanisms
underlying GPCRs and DOR membrane trafficking, and the analgesic function of emerged DOR
through membrane trafficking under certain pathophysiological circumstances.
Introduction
Currently, opioids are still the most effective analgesics
available in the clinical treatment of moderate and severe
pain. Pharmacological and molecular cloning studies
have clearly established three classic types of opioid recep-
tors, μ (MOR), δ, and κ (KOR), which belong to the super-
family of GPCRs with seven transmembrane domains. All
three opioid receptors are involved in major opioid
actions, including analgesia, reward, and the develop-
ment of analgesic tolerance and physical dependence [1].
At present, most clinically used opioids for analgesia are
either nonselective opioid agonists or selective MOR ago-
nists. The analgesic efficacy of currently used opioid anal-
gesics is generally limited due to their tendency to cause
analgesic tolerance, physical dependence and other unde-
sirable side effects after prolonged and repeated use.
Traditionally, DOR agonists have been regarded as very
weak analgesics with minimal potential of being used
clinically for pain relief although they may produce fewer
undesirable side effects than MOR agonists [2]. In animal
studies, the analgesic effect of DOR agonists has not been
consistently clarified. In opioid naïve animals, although
activation of DOR in the spinal cord produces antinocice-
ption [3], the effect of DOR agonists applied in the
supraspinal sites is inconsistent. Microinjection of DOR
agonists into the nucleus raphe magnus (NRM) in the
medulla or periaqueductal gray (PAG) in the midbrain
produces little or weak antinociceptive effects in normal
animals [4-7]. However, a significant antinociceptive
effect mediated by DOR in the NRM through its descend-
ing pain-modulating system has been reported recently in
rats after repeated morphine treatment [4]. The lack of
DOR analgesia in normal conditions has been largely
attributed to the normally intracellular localization of
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DOR. Interestingly, several behavioral conditions have
been found to induce DOR membrane trafficking and
enhance DOR analgesia, including chronic inflammatory
or neuropathic pain [8-12], prolonged morphine treat-
ment [3,4,11,13-15], and stress [16].
As a member of the family A GPCRs, DOR, once synthe-
sized intracellularly or internalized upon agonist stimula-
tion, is subject to the process of intracellular sorting
through either proteolysis in lysosomes or recycling to cell
surface. Unlike MOR, which is normally expressed on the
cell surface membrane, DOR is predominantly located in
the intracellular compartments in most central neurons
under normal conditions [17-19]. However, recent evi-
dence has shown that certain stimuli, such as DOR ago-
nists and chronic pain, can trigger intracellular signals to
promote the sorting pathway for DOR membrane traffick-
ing, and enable the emerged DOR on surface membrane
to exert physiological functions. Here in this review, we
summarize recent reports of DOR membrane trafficking
and its functional significance, including basic processes
and modulation of DOR membrane trafficking, and
behavioral conditions that may induce the membrane
trafficking of DOR, and particularly, the DOR in the
brainstem for descending inhibition of pain.
Mechanisms of opioid receptor trafficking
Basic concepts of GPCR trafficking
Upon agonist binding and stimulation, most GPCRs
undergo phosphorylation and internalization through
clathrin-coated pits [19] (Figure 1). Once internalized, the
receptor may undertake either of the two trafficking fates:
being rapidly recycled back to the plasma membrane
(recycling pathway), or being targeted to lysosomes for
proteolysis (degradative pathway) [20,21]. In the recy-
cling pathway, which is the default trafficking route for
MOR,  β2-adrenergic receptors and NK1 receptors, the
receptor dissociates from the ligand in the acidic pH of the
endosomal compartment, is dephosphorylated and sub-
sequently returned to the plasma membrane. By contrast,
in the lysosomal pathway, which is the preferred sorting
pathway for DOR and the protease-activated receptor 1
(PAR-1), the receptor is targeted for degradation in lyso-
somes. The process of intracellular sorting of GPCRs to
recycling endosomes or lysosomal degradation compart-
ments involves complex protein-protein interactions, and
is subjected to modulations through intrinsic receptor
motifs, intracellular signaling pathways and several pro-
tein kinases. These regulatory factors essentially control
the rate of receptor internalization, recycling or lysosomal
degradation, and consequently the magnitude and dura-
tion of receptor signaling.
Structural determinants of GPCR trafficking related to 
intracellular degradation
Accumulating evidence has revealed that the final fates of
intracellular GPCRs, either to surface membrane for recy-
cling or to lysosomes for degradation, are crucially deter-
mined by intrinsic recognition mechanisms between
specific motifs in the cytoplasmic domains of GPCRs, par-
ticularly in the carboxyl terminus, and intracellular inter-
acting adaptors named sorting proteins [22,23]. For DOR,
it is believed that the interaction between the cytoplasmic
carboxyl tail and certain sorting proteins, such as GPCR-
associated sorting protein (GASP) [23,24], may lead the
receptor sorting to the default degradation pathway under
naïve conditions.
Similar to other GPCRs, DOR has a common molecular
topology including a hydrophobic core of seven mem-
brane-spanning α-helices, three intracellular loops, three
extracellular loops, an extracellular amino terminus, and
an intracellular carboxyl terminus [1]. A small conserved
region within the cytoplasmic carboxyl tail serves as a crit-
ical recognition site for DOR interaction with sorting pro-
teins, such as GASP, in the determination of its lysosomal
sorting and proteolysis after agonist stimulation and
internalization [22-24]. This carboxyl terminal containing
the conserved motif NPXXY has higher binding affinity
for the lysosome-targeting sorting proteins GASP and sort-
ing nexin-1 (SNX-1), but relatively lower binding affinity
for the recycling sorting protein N-ethylmaleimide-sensi-
tive factor (NSF), and even undetectable binding affinity
for the recycling sorting protein Ezrin-radixin-moesin
(ERM)-binding phosphoprotein-50/Na+/H+  exchanger
regulatory factor-1 (EBP50/NHERF-1) [22,24]. Con-
versely, the carboxyl terminal of β2-adrenergic receptors
shows higher affinity for the recycling sorting proteins
EBP50/NHERF and NSF, but lower affinity for GASP and
SNX-1 [22]. The interaction between the carboxyl termi-
nal of GPCRs and specific sorting proteins may critically
determine the sorting fate of intracellular GPCRs. For
example, chimeric exchange of the C-terminus of MOR
and DOR has been shown to dramatically divert the sort-
ing fate of these two opioid receptors [23].
Sorting proteins
Sorting proteins of GPCRs are a number of intracellular
adaptors or scaffolding proteins proposed to govern the
differential sorting events, and generally have relatively
high affinity for the carboxyl terminus of GPCRs. Sorting
proteins decisively influence the post-endocytic fate of
GPCRs via interaction with the C-tail domains of a recep-
tor, which is well exemplified by the sorting protein GASP
that determines the lysosomal sorting of DOR [23] and
dopamine D2 receptors [25]. GASP is an intracellular pro-
tein with 1395 residues and belongs to a novel family of
proteins containing a conserved 250-residue carboxyl ter-Molecular Pain 2007, 3:37 http://www.molecularpain.com/content/3/1/37
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minal domain [24]. Disrupting the interaction between
GASP and the carboxyl terminal tail of DOR or D2 recep-
tors reroutes their post-endocytic sorting from normally a
degradative lysosomal fate to the recycling pathway
[23,25]. Meanwhile, chimeric studies have revealed that
replacement of the sequence in the C-tail of DOR with the
corresponding sequence of MOR is sufficient to impart
the recycling property of MOR for DOR in HEK293 cells
[23]. Taken together, these findings identify GASP as a key
protein to determine the degradative fate of some GPCRs,
including DOR.
Similarly, SNX-1 is another candidate sorting protein
involved in targeting GPCRs, including DOR, to the deg-
radative pathway [20,22], as it has a low affinity for
GPCRs that prefer the recycling pathway [26]. It serves as
a key determinant for PAR-1 that is preferentially targeted
to lysosomes. Other candidates of lysosome targeting sort-
ing proteins include ubiquitination [20] and rab7
[20,27,28].
In contrast, other sorting proteins, such as EBP50/NHERF-
1, promote intracellular GPCRs to the recycling pathway.
EBP50/NHERF-1 contains two PSD-95/Disc-large/ZO-1
homology (PDZ) domains and one ERM domain. PDZ
domains bind to the C-terminal of GPCRs and ERM
domain interacts with intracellular actin cytoskeleton
[27], thereby mediating the trafficking of targeted proteins
to plasma membrane. Previous studies have established
that binding of the PDZ domains of EBP50/NHERF-1
with the C-terminal of certain GPCRs, including KOR and
β2-adrenergic receptors [27,29], may direct their mem-
Mechanisms of membrane trafficking for G-protein-coupled receptors (GPCRs) Figure 1
Mechanisms of membrane trafficking for G-protein-coupled receptors (GPCRs). Upon agonist binding (1), a GPCR, including 
the delta-opioid receptor (DOR), is phosphorylated by GPCR kinases (GRK) (2), binds to proteins AP-2 and arrestin (3), and 
undergoes the process of internalization via endocytosis through clathrin-coated pit (4). Once internalized, the receptor is sub-
jected to highly regulated sorting processes and is targeted either to endosomes in the recycling pathway (5) for membrane 
insertion, or to lysosomes for degradation through the degradation pathway (6). DOR is synthesized in the endoplasmic retic-
ulum (ER) (7), then transported to the trans-Golgi network (8) through ER-Golgi complex, and becomes a mature receptor. 
Matured DOR is normally targeted intracellularly in large dense-core vesicles (9) as intracellular pool of DOR ready for mem-
brane trafficking and insertion. Chronic pain conditions induce the release of a number of inflammatory mediators, which acti-
vate corresponding receptors (10) and increase intracellular calcium concentration, causing the membrane trafficking of DOR. 
Persistent stimulation of mu-opioid receptors (MOR) by chronic opioids (11) can induce the membrane trafficking of intracel-
lular DOR and bring out functional DOR through yet unknown mechanisms.
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brane trafficking. Similarly, NSF [30] and Rab GTPases
[28] also serve as the sorting proteins to mediate mem-
brane trafficking of intracellular GPCRs. However, it is
currently unknown what recycling sorting proteins are
involved in the diversion of DOR trafficking from a nor-
mal lysosomal fate to the recycling pathway under certain
behavioral conditions mentioned above.
Endoplasmic reticulum (ER) – Golgi apparatus network-
disturbing agents
Intracellular GPCRs, particularly DOR that is normally
targeted intracellularly, are synthesized, folded in the ER
and then packaged into ER-derived vesicles. These trans-
port vesicles carrying cargo receptors then migrate from
the ER to the ER-Golgi intermediate complex, the Golgi
apparatus and the trans-Golgi network (TGN) (Figure 1).
During this process, receptors undergo post-translational
modifications (e.g. glycosylation) to attain mature status.
Thereafter, the mature receptors, under precise regulation
by intracellular signals, move from the TGN to the plasma
membrane via large dense-core vesicles (LDCVs) through
yet unidentified mechanisms. Any manipulations disrupt-
ing the functions of ER-TGN network may significantly
influence the membrane trafficking of GPCRs. Brefeldin
A, a Golgi-disturbing agent [31], is capable of diminishing
MOR membrane insertion induced by activation of the
cAMP-PKA pathway in brainstem neurons [32] as well as
DOR membrane trafficking induced by neurotrophin in
PC12 cells [18].
Bradykinin and inflammatory mediators
Bradykinin is a proinflammatory mediator involved in a
series of pathophysiological processes including chronic
pain. It exerts most of its biological effects by interacting
with two classes of GPCRs termed as B1 and B2. The intra-
cellular signaling pathway activated by bradykinin via B2
receptors exhibits the potency to induce membrane inser-
tion of intercellular DOR as measured by DOR inhibition
of both the evoked neuropeptide exocytosis and the stim-
ulated adenylyl cyclase activity in cultured rat trigeminal
ganglion neurons; these actions of bradykinin are medi-
ated through the protein kinase C (PKC)-dependent sign-
aling pathway [17]. Furthermore, other proinflammatory
agents, such as ATP and capsaicin, are also shown to
induce DOR insertion into the plasma membrane in dor-
sal root ganglion (DRG) neurons [33] (Figure 1).
Substance P
Substance P is the first pronociceptive neuropeptide iden-
tified in primary sensory neurons, and is also involved in
the modulation of DOR membrane trafficking. The sub-
stance P domain of preprotachykinin A (PPT-A) directly
interacts with the third luminal domain of DOR, and this
interaction is required for DOR sorting into LDCVs for
membrane insertion in DRG neurons and in cultured cell
lines [34,35]. Knockout of PPT-A  eliminates agonist-
induced DOR membrane insertion in isolated DRG neu-
rons, and abolishes analgesia induced by intrathecal injec-
tion of a DOR agonist in intact animal [34], confirming
the critical involvement of substance P in the process of
DOR membrane trafficking in sensory neurons.
Neurotrophins
Activation of the TrkA signaling pathway by nerve growth
factor (NGF) regulates the later (post-ER) events in the
anterograde trafficking of intracellular DOR, which is
required to maintain the intracellular pool of DOR avail-
able for plasma membrane insertion [18]. It has been
shown that the cytoplasmic domain in the C-terminal of
DOR (27 amino acid residues) contains a signal that
determines the specificity of NGF-regulated intracellular
targeting of the receptor. Epidermal growth factor (EGF)
also can promote the rapid translocation of transient
receptor potential (TRP) channel C5, although not a
GPCR, inducing its insertion into the plasma membrane
via activation of the phosphatidylinositide 3-kinase
(PI3K) and Rac1, a Rho family GTPase commonly
involved in cytoskeletal re-arrangements and initiation of
cell morphological changes [36].
Calcium entry and intracellular calcium store
Because intracellular calcium plays a key role in the traf-
ficking and membrane fusion of protein-containing vesi-
cles, it is conceivable that intracellular calcium signaling is
also crucially involved in DOR membrane insertion, espe-
cially in the premise that intracellular DOR is predomi-
nately located in the LDCVs [33]. In cultured DRG
neurons, either depression of extracellular calcium entry
or depletion of intracellular inositol (1,4,5)-trisphosphate
(IP3)-sensitive calcium stores abolishes DOR membrane
insertion induced by DOR agonists; meanwhile, the
upsurge of intracellular calcium produced by capsaicin,
ATP, and high potassium-induced depolarization pro-
motes the membrane insertion of intracellular DOR
[18,33,35]. Although the definite role of intracellular cal-
cium in the membrane trafficking of GPCRs has not yet
been clearly defined, it is generally postulated that cal-
cium is critically involved, at least, in the process of vesicle
transport, cytoskeleton arrangement and membrane
fusion.
Protein kinases
Protein kinases are also found to modulate the trafficking
and membrane insertion of GPCRs including DOR. Acti-
vation of the cAMP-PKA pathway by the adenylyl cyclase
activator forskolin or the nonhydrolysable cAMP analog
8-bromo-cAMP promotes MOR membrane trafficking
and consequently MOR inhibition of presynaptic GABA
release in rat dorsal motor nucleus of the vagus neurons,
an effect blocked by the cAMP-PKA pathway inhibitorMolecular Pain 2007, 3:37 http://www.molecularpain.com/content/3/1/37
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H89 [32]. However, forskolin activation of the cAMP-PKA
pathway fails to induce functional membrane trafficking
of DOR in midbrain PAG neurons [13]. PKC, conceivably
involved in membrane trafficking and insertion of gluta-
mate receptors, has also been identified to mediate the
bradykinin-induced membrane insertion of DOR in rat
sensory neurons [17]. To date, the involvement of other
protein kinases, such as MAP kinases and calmodulin
kinases, in membrane trafficking of opioid receptors has
yet to be explored.
Although many regulatory factors have been identified to
critically modulate the intracellular sorting and mem-
brane insertion of GPCRs including DOR in naïve condi-
tions, it remains unknown whether and how these
regulatory factors trigger and mediate DOR membrane
trafficking induced under several pathophysiological cir-
cumstances such as chronic pain and prolonged opioid
exposure, as described below.
Opioid receptor trafficking and pain modulation
Pain-induced opioid receptor trafficking and pain 
inhibition
Peripheral sensory neurons in the DRG are nociceptors
that receive nociceptive stimuli and deliver the nocicep-
tive information to the modulatory circuits in the spinal
dorsal horn. As mentioned above, inflammatory media-
tors, such as bradykinin [17], substance P [34] and ATP
[33], can induce DOR membrane trafficking in cultured
sensory neurons in vitro. Sustained inflammation induced
by complete Freud's adjuvant (CFA) also significantly
increases DOR membrane trafficking in small- and
medium-sized DRG neurons in intact animals [11]. Local
administration of capsaicin, an activator of vanilloid/tran-
sient receptor potential vanilloid 1 (TRPV1) selectively
located in C-fibers, induces an increase in DOR mem-
brane trafficking in small-sized DRG neurons [11], sug-
gesting that the enhanced membrane recruitment of DOR
is tightly adapted to the modality of pain, and may
account for the enhanced antinociceptive efficacy of DOR
agonists under that condition. Additionally, there is a
bilateral upregulation in DOR expression in the DRG neu-
rons of small and large diameters from rats after chronic
constriction of the sciatic nerve, resulting in DOR-medi-
ated inhibition of tactile allodynia following nerve injury
[8].
The dorsal horn, especially lamina II, of the spinal cord is
a critical site for the relay and processing of dynamic sen-
sory information. While spinal administration of DOR
agonists induces antinociception in naïve animals [15],
DOR-mediated analgesic effects that reverse hyperalgesia
and tactile allodynia are dramatically augmented in ani-
mals with chronic inflammatory or neuropathic pain
[15,37]. Likely, this results from the increased membrane
recruitment of DOR in the dorsal horn neurons following
the chronic pain. Actually, sustained inflammation
induced by CFA is also reported to significantly increase
the expression and membrane targeting of DOR in the spi-
nal dorsal horn where the analgesic effect of DOR agonists
is largely enhanced [9,10]. This adaptation of DOR during
chronic inflammation may require the integrity of MOR
as this adaptation is diminished in MOR knockout mice
[9]. Also, increased membrane trafficking of functional
DOR has been reported in laminas III-VI neurons from
rhizotomized rats [14].
Several brain regions including the PAG and NRM are crit-
ical sites for supraspinal pain modulation. Pharmacologi-
cal and electrophysiological evidence has established that
the brainstem NRM, receiving major inputs from the PAG,
functions as an integral relay in descending modulation of
nociception. In these brain regions, DOR is located pre-
dominantly in presynaptic axon terminals, rather than on
plasma membrane of presynaptic boutons, and immu-
nolabeling for DOR is often associated with intracellular
LDCVs [38-40]. In general, the analgesic effect of DOR
agonists applied in these two regions is weak in normal
animals. Although local microfusion of DOR agonists
into the NRM region shows an inhibition of the tail flick-
related increase in ON-cell activity and shortens the tail
flick-related pause in OFF-cell activity in intact animals
[41], microinjection of DOR agonists into either the PAG
or NRM has only little or a weak effect on the thermal
nociception in normal rats [4,6]. However, persistent
inflammation induced by CFA markedly increases the
anti-hyperalgesic potency of DOR agonists applied in the
NRM, as indicated by a prolonged effect duration and a
leftward shift of the dose-response curve with a reduced
ED50 value, an effect appearing two weeks after inflamma-
tory injury [12]. Also, microinjection of the DOR antago-
nist naltriben into the NRM enhances the hyperalgesia in
the ipsilateral hindpaw, which is at least partially medi-
ated by the increased release of endogenous opioid pep-
tides with preferential affinity for DOR [42]. In addition,
microinjection of DOR agonists into the ventral PAG sig-
nificantly inhibits mechanical allodynia in rats with neu-
ropathic pain [43]. Nevertheless, there is no data currently
available regarding the mechanisms for the adaptation
and membrane trafficking of DOR induced by chronic
pain in the supraspinal sites critically involved in pain
modulation.
Opioid-induced DOR trafficking and opioid analgesia
Peripheral sensory neurons in the DRG are among the
critical targets of opioid analgesics acting on opioid recep-
tors, including MOR and DOR, abundantly expressed in
the cell body and terminals of DRG neurons [33]. It has
been described recently that DOR agonists can rapidly
induce the membrane trafficking of intracellular DOR viaMolecular Pain 2007, 3:37 http://www.molecularpain.com/content/3/1/37
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Ca2+-dependent signaling pathways in cultured sensory
neurons [33]. Prolonged exposure to morphine (48
hours) also significantly increases DOR membrane traf-
ficking in cultured DRG neurons [11] and cortical neu-
rons [3]. Similarly, sustained systemic treatment with
morphine significantly induces the membrane transloca-
tion of intracellular DOR in sensory neurons in intact
mice [11]. It is believed that the DOR membrane recruit-
ment accounts, at least in part, for the enhanced antinoc-
iceptive efficacy of DOR agonists following sustained
morphine treatment, and may provide a more effective
action site for peripheral analgesics [3].
Spinal dorsal horn, as the primary processing center for
nociceptive information, also contains abundant opioid
receptors, therefore serving as another critical site for opi-
oid analgesia. DOR in the spinal neurons is mostly,
although not exclusively, associated with the intracellular
compartments in control conditions [3,44]. Repeated
treatment with morphine or other selective MOR agonists
induces MOR-dependent membrane insertion of DOR,
and increases the bioavailability of DOR in the cultured
[3] and in vivo [3,14,44] spinal neurons. The increase in
functional DOR on surface membrane is thought respon-
sible for the enhanced, DOR agonist-mediated antinocic-
eption after chronic opioid treatment [3,44,45].
Through their descending pathways for pain modulation,
the brainstem NRM and the midbrain PAG serve as the
critical supraspinal sites for opioid analgesia. Despite the
abundant expression of DOR in these areas [19,38,39,46],
little DOR-mediated cellular actions have been observed
under normal conditions, likely due to the intracellular
location of these receptors in these two brain regions in
naïve animals [4,47]. However, others have reported a
DOR-induced weak potassium current in a small popula-
tion of NRM and PAG neurons [48,49], but DOR agonists
have no significant effect on the presynaptic GABA release
in these NRM or PAG neurons from normal animals
[4,13,49]. Intriguingly, several recent studies have
revealed that the intracellular DOR can translocate to the
surface membrane and become functional in these neu-
rons from rats chronically treated with morphine [4,13]
(Figure 1). In these neurons, DOR agonists elicit a signifi-
cant inhibition of presynaptic GABA release through acti-
vation of the newly inserted, functional DOR, which is
absent in normal animals [4,13]. The behavioral signifi-
cance of this membrane trafficking of DOR in the NRM
has been functionally demonstrated by the observations
that microinjection of DOR agonists into the NRM, inef-
fective in opioid naïve animals, produces significant anti-
nociception in chronic morphine-treated animals, and
relieves analgesic tolerance to chronic morphine [4].
These observations further support the notion that DOR
agonists may be more effective and therefore could serve
as better alternative analgesics for pain control following
chronic exposure to MOR agonists.
Conclusion
It is now well documented that DOR is predominantly
located in the intracellular compartments in most neu-
rons within the pain-related central circuits in control
conditions, and a number of behavioral stimuli, espe-
cially chronic pain and prolonged opioid exposure, can
induce the membrane trafficking of DOR. The mecha-
nisms underlying membrane trafficking of GPCRs includ-
ing DOR are still perplexing and poorly understood at
present. They may involve precise interactions among the
receptor motifs, sorting proteins, inflammatory mediators
and intracellular signaling pathways under certain physi-
ological and pathophysiological conditions. Better under-
standing of the mechanisms and underlying signals and
conditions for induction of DOR membrane trafficking
would promise the development of more efficacious opi-
oid analgesics with fewer side-effects.
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